MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

An Exploratory Study to Assess the Effects of JNJ-39439335 on the Relief of Pain Using a Thermal-Grill Experimental Model

Phase 1
Completed
Conditions
Pain
First Posted Date
2009-11-01
Last Posted Date
2010-07-02
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
12
Registration Number
NCT01006304

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Phase 2
Terminated
Conditions
Diabetic Neuropathy
Interventions
Drug: JNJ-42160443 (3 mg)
Drug: JNJ-42160443 (10 mg)
Drug: Placebo
Drug: JNJ-42160443 (1 mg)
First Posted Date
2009-10-09
Last Posted Date
2016-06-03
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
77
Registration Number
NCT00993018

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

Phase 3
Completed
Conditions
Gastroesophageal Reflux
Interventions
First Posted Date
2009-10-09
Last Posted Date
2013-05-22
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
344
Registration Number
NCT00992589

A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders

Phase 1
Completed
Conditions
Bipolar Disorder
Interventions
First Posted Date
2009-09-29
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
56
Registration Number
NCT00986336

A Pharmacokinetic Study of Lithium Before and During Topiramate Dosing in Bipolar Disorder Patients

Phase 1
Completed
Conditions
Bipolar Disorder
Interventions
First Posted Date
2009-09-29
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
32
Registration Number
NCT00986128

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain

Phase 2
Terminated
Conditions
Low Back Pain
Low Back Pain, Recurrent
Interventions
Drug: JNJ-42160443 1 mg
Drug: JNJ-42160443 10 mg
Drug: JNJ-42160443 3 mg
Drug: JNJ-42160443 6 mg/3mg
Drug: Matching Placebo
First Posted Date
2009-09-09
Last Posted Date
2016-06-06
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
389
Registration Number
NCT00973024

A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain

Phase 2
Terminated
Conditions
Osteoarthritis
Osteoarthritis, Hip
Pain
Osteoarthritis, Knee
Arthralgia
Joint Pain
Interventions
Drug: Placebo
First Posted Date
2009-09-09
Last Posted Date
2020-03-11
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
467
Registration Number
NCT00973141

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Phase 2
Terminated
Conditions
Pain
Neuralgia
Mononeuropathies
Neuralgia, Postherpetic
Interventions
Drug: Placebo
First Posted Date
2009-08-25
Last Posted Date
2016-05-02
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
112
Registration Number
NCT00964990

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2009-08-24
Last Posted Date
2014-04-23
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
116
Registration Number
NCT00963768

A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2009-07-27
Last Posted Date
2014-04-29
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
116
Registration Number
NCT00946569
© Copyright 2025. All Rights Reserved by MedPath